The appropriateness of routine medication treatment for schizophrenia

Schizophrenia Bulletin

Volumn 36, Issue 4, 2010, Pages 732-739

  Young, Alexander S ^b   Niv, Noosha ^a,b   Cohen, Amy N ^a   Kessler, Christopher ^b,c   McNagny, Kirk ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Antipsychotics; Community mental health; Drug side effects; Health service research; Quality measurement; Quality of care; Weight management

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; MALE; MENTAL HEALTH CENTER; MULTICENTER STUDY; OBESITY; PARKINSONISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; WEIGHT GAIN; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CHRONIC DISEASE; COMORBIDITY; DYSKINESIA; HEALTH CARE QUALITY; LONGITUDINAL STUDY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGY;

NEUROLEPTIC AGENT;

ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CHRONIC DISEASE; COMORBIDITY; DEPRESSIVE DISORDER; DYSKINESIA, DRUG-INDUCED; FEMALE; GUIDELINE ADHERENCE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY ASSURANCE, HEALTH CARE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77958178617     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn138     Document Type: Article

References (52)

1. American Psychiatric Association. Practice guideline for thetreatment of patients with schizophrenia 2nd edition. Am J Psychiatry. 2004;161:1-56.
2. LehmanAF, Kreyenbuhl J, BuchananRW, et al.TheSchizophreniaPatient Outcomes Research Team (PORT): updated treatmentrecommendations 2003. Schizophr Bull. 2004;30:193-217.
3. Miller AL, Hall CS, Buchanan RW, et al. The Texas MedicationAlgorithm Project antipsychotic algorithm for schizophrenia:2003 update. J Clin Psychiatry. 2004;65:500-508.
4. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 1993;19:287-302.
5. Lehman AF. Quality of care in mental health: the case of schizophrenia. Health Aff (Millwood). 1999;18:52-65.
6. Institute of Medicine. Improving the Quality of Health CareforMental and Substance-Use Conditions: Quality Chasm Series.Washington, DC: National Academies Press; 2006.
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
8. Tandon R, Belmaker RH, Gattaz WF, et al. World PsychiatricAssociation Pharmacopsychiatry Section statement oncomparative effectiveness of antipsychotics in the treatmentof schizophrenia. Schizophr Res. 2008;100:20-38.
9. Marder SR, Essock SM, Miller AL, et al. Physical healthmonitoring of patients with schizophrenia. Am J Psychiatry.2004;161:1334-1349.
10. Young AS, Sullivan G, Duan N. Patient, provider, and treatmentfactors associated with poor-quality care for schizophrenia.Ment Health Serv Res. 1999;1:201-211.
11. Leslie DL, Rosenheck RA. Adherence of schizophrenia pharmacotherapyto published treatment recommendations: patient, facility, and provider predictors. Schizophr Bull. 2004;30:649-658.
12. Hoge MA, Paris M, Jr., Adger H, Jr, et al. Workforce competenciesin behavioral health: an overview. Adm PolicyMent Health. 2005;32:593-631.
13. Cramer JA, Rosenheck R. Compliance with medication regimensfor mental and physical disorders. Psychiatr Serv.1998;49:196-201.
14. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy dataidentify poorly adherent patients with schizophrenia at increasedrisk for admission. Med Care. 2002;40:630-639.
15. Cradock J, Young AS, Sullivan G. The accuracy of medicalrecord documentation in schizophrenia. J Behav HealthServ Res. 2001;28:456-465.
16. Young AS. Routinely measuring schizophrenia treatmentquality-shortcomings with medical records. Med Care.2007;45:104.
17. Lehman AF, Steinwachs DM. Patterns of usual care forschizophrenia: initial results from the Schizophrenia PatientOutcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998;24:11-20.
18. Fischer EP, Owen RR. Quality of public sector care forschizophrenia in Arkansas. Ment Health Serv Res. 1999;1:213-221.
19. Rosenheck RA, Desai R, Steinwachs D, Lehman A. Benchmarkingtreatment of schizophrenia: a comparison of servicedelivery by the national government and by state and localproviders. J Nerv Ment Dis. 2000;188:209-216.
20. Young AS. Evaluating and improving the appropriateness of treatment for schizophrenia. Harvard Review of Psychiatry.1999;7:114-118.
21. Young AS, Sullivan G, Burnam MA, Brook RH. Measuringthe quality of outpatient treatment for schizophrenia. ArchGen Psychiatry. 1998;55:611-617.
22. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, WennbergDE, Lucas FL. Surgeon volume and operative mortalityin the United States. N Engl J Med. 2003;349:2117-2127.
23. Young AS, Mintz J, Cohen AN, Chinman MJ. A networkbasedsystem to improve care for schizophrenia: the medicalinformatics network tool (MINT). J Am Med Inform Assoc.2004;11:358-367.
24. Brown AH, Cohen AN, Chinman MJ, Kessler C, Young AS.EQUIP: implementing chronic care principles and applyingformative evaluation methods to improve care for schizophrenia:QUERI Series. Implementation Science. 2008;3:9.
25. First MB, Spitzer RL, Gibbon M, Williams JBW. StructuredClinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Patient Edition, Version 2.0.New York, NY: New York State Psychiatric Institute; 1995.
26. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J.Training and quality assurance with the Structured ClinicalInterview for DSM-IV (SCID-I/P). Psychiatry Res. 1998;79:163-173.
27. Ventura J, Green MF, Shaner A, Liberman RP. Training andquality assurance with the Brief Psychiatric Rating Scale: ''thedrift busters. Int J Methods Psychiatr Res. 1993;3:221-244.
28. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
29. Munetz MR, Benjamin S. How to examine patients using theAbnormal Involuntary Movement Scale. Hosp Commun Psychiatry.1988;39:1172-1177.
30. American Diabetes Association.Consensus development conferenceon antipsychotic drugs and obesity and diabetes. DiabetesCare. 2004;27:596-601.
31. Newcomer JW. Metabolic considerations in the use of antipsychoticmedications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27.
32. Weiden PJ. Switching antipsychotics as a treatment strategyfor antipsychotic-induced weight gain and dyslipidemia.J Clin Psychiatry. 2007;68(suppl 4):34-39.
33. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia.Arch Gen Psychiatry. 1982;39:486-487.
34. Marder SR, Essock SM, Miller AL, et al. The Mount Sinaiconference on the pharmacotherapy of schizophrenia. Schizophr Bull. 2002;28:5-16.
35. Jeste DV. Tardive dyskinesia rates with atypical antipsychoticsin older adults. J Clin Psychiatry. 2004;65(suppl 9):21-24.
36. Rosenheck RA, Banks S, Pandiani J, Hoff R. Bed closuresand incarceration rates among users of Veterans Affairs mentalhealth services. Psychiatr Serv. 2000;51:1282-1287.
37. Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM.Clinicians' recognition of the metabolic adverse effects of antipsychoticmedications. Schizophr Res. 2005;79:281-288.
38. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical AntipsychoticTherapy and Metabolic Issues National Survey:practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol.2004;24:S1-6.
39. Motsinger C, Slack M, Weaver M, Reed M. Physician patternsof metabolic screening for patients taking atypical antipsychotics:a retrospective database study. Primary carecompanion to the Journal of clinical psychiatry. 2006;8:220-223.
40. Davidson MH, Hauptman J, DiGirolamo M, et al. Weightcontrol and risk factor reduction in obese subjects treatedfor 2 years with orlistat: a randomized controlled trial.JAMA. 1999;281:235-242.
41. Gordon A, Price LH. Mood stabilization and weight loss withtopiramate. Am J Psychiatry. 1999;156.
42. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitorfor the management of obesity. Pharmacotherapy.2000;20:270-279.
43. McMahon FG, Fujioka K, Singh BN, et al. Efficacy andsafety of sibutramine in obese white and African Americanpatients with hypertension: a 1-year, double-blind, placebocontrolled, multicenter trial. Arch Intern Med. 2000;160:2185-2191.
44. Norton J, Potter D, Edwards K. Sustained weight loss associatewith topiramate. Epilepsia. 1997;38:58.
45. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and preventionof weight regain in obese patients. European MulticentreOrlistat Study Group. Lancet. 1998;352:167-172.
46. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, JohnsonCG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh. 2003;35:237-241.
47. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associatedweight gain: 12-month data on a multimodal weight controlprogram. J Clin Psychiatry. 2004;65:471-477.
48. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gainassociated with atypical antipsychotics. Psychiatr Serv.2003;54:1155-1157.
49. Faulkner G, Cohn T, Remington G. Interventions to reduceweight gain in schizophrenia. Schizophr Bull. 2007;33:654-656.
50. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone inpatients with chronic schizophrenia who did not respond toprior atypical antipsychotic treatment. Am J Psychiatry.2006;163:600-610.
51. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole inoverweight subjects with schizophrenia or schizoaffective disorderswitched from olanzapine. J Clin Psychiatry. 2008;e1-e11.
52. Leslie DL, Rosenheck RA. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Departmentof Veterans Affairs and the private sector. J MentHealth Policy Econ. 2003;6:113-121.